Marked improvement with sildenafil in a patient with primary pulmonary hypertension unresponsive to epoprostenol

Masaharu Kataoka; Toru Satoh; Tomohiro Manabe; Toshihisa Anzai; Tsutomu Yoshikawa; Hideo Mitamura; Satoshi Ogawa

doi:10.2169/internalmedicine.43.945

Marked improvement with sildenafil in a patient with primary pulmonary hypertension unresponsive to epoprostenol

Masaharu Kataoka, Toru Satoh, Tomohiro Manabe, Toshihisa Anzai, Tsutomu Yoshikawa, Hideo Mitamura, Satoshi Ogawa

Research output: Contribution to journal › Article › peer-review

8 Citations (Scopus)

Abstract

We report a 48-year-old woman with right heart failure due to primary pulmonary hypertension. Continuous infusion of epoprostenol (prostaglandin I₂) for 1.5 years failed to control her condition, but she was later successfully treated with additional sildenafil for a few months. Her mean pulmonary artery pressure was originally 57 mmHg, increased to 62 mmHg with epoprostenol, and decreased to 45 mmHg with sildenafil. Additional sildenafil may be an effective and life-saving agent in patients with primary pulmonary hypertension who show a poor response to epoprostenol, which is considered to be very powerful medical treatment for the disease.

Original language	English
Pages (from-to)	945-950
Number of pages	6
Journal	Internal Medicine
Volume	43
Issue number	10
DOIs	https://doi.org/10.2169/internalmedicine.43.945
Publication status	Published - 2004 Oct 1

Keywords

Epoprostenol
Primary pulmonary hypertension
Right heart failure
Sildenafil

ASJC Scopus subject areas

Internal Medicine

Access to Document

10.2169/internalmedicine.43.945

Cite this

@article{29721cc2306144d4b8e542d0f549c56e,

title = "Marked improvement with sildenafil in a patient with primary pulmonary hypertension unresponsive to epoprostenol",

abstract = "We report a 48-year-old woman with right heart failure due to primary pulmonary hypertension. Continuous infusion of epoprostenol (prostaglandin I2) for 1.5 years failed to control her condition, but she was later successfully treated with additional sildenafil for a few months. Her mean pulmonary artery pressure was originally 57 mmHg, increased to 62 mmHg with epoprostenol, and decreased to 45 mmHg with sildenafil. Additional sildenafil may be an effective and life-saving agent in patients with primary pulmonary hypertension who show a poor response to epoprostenol, which is considered to be very powerful medical treatment for the disease.",

keywords = "Epoprostenol, Primary pulmonary hypertension, Right heart failure, Sildenafil",

author = "Masaharu Kataoka and Toru Satoh and Tomohiro Manabe and Toshihisa Anzai and Tsutomu Yoshikawa and Hideo Mitamura and Satoshi Ogawa",

year = "2004",

month = oct,

day = "1",

doi = "10.2169/internalmedicine.43.945",

language = "English",

volume = "43",

pages = "945--950",

journal = "Internal Medicine",

issn = "0918-2918",

publisher = "Japanese Society of Internal Medicine",

number = "10",

}

TY - JOUR

T1 - Marked improvement with sildenafil in a patient with primary pulmonary hypertension unresponsive to epoprostenol

AU - Kataoka, Masaharu

AU - Satoh, Toru

AU - Manabe, Tomohiro

AU - Anzai, Toshihisa

AU - Yoshikawa, Tsutomu

AU - Mitamura, Hideo

AU - Ogawa, Satoshi

PY - 2004/10/1

Y1 - 2004/10/1

N2 - We report a 48-year-old woman with right heart failure due to primary pulmonary hypertension. Continuous infusion of epoprostenol (prostaglandin I2) for 1.5 years failed to control her condition, but she was later successfully treated with additional sildenafil for a few months. Her mean pulmonary artery pressure was originally 57 mmHg, increased to 62 mmHg with epoprostenol, and decreased to 45 mmHg with sildenafil. Additional sildenafil may be an effective and life-saving agent in patients with primary pulmonary hypertension who show a poor response to epoprostenol, which is considered to be very powerful medical treatment for the disease.

AB - We report a 48-year-old woman with right heart failure due to primary pulmonary hypertension. Continuous infusion of epoprostenol (prostaglandin I2) for 1.5 years failed to control her condition, but she was later successfully treated with additional sildenafil for a few months. Her mean pulmonary artery pressure was originally 57 mmHg, increased to 62 mmHg with epoprostenol, and decreased to 45 mmHg with sildenafil. Additional sildenafil may be an effective and life-saving agent in patients with primary pulmonary hypertension who show a poor response to epoprostenol, which is considered to be very powerful medical treatment for the disease.

KW - Epoprostenol

KW - Primary pulmonary hypertension

KW - Right heart failure

KW - Sildenafil

UR - http://www.scopus.com/inward/record.url?scp=8844256580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8844256580&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.43.945

DO - 10.2169/internalmedicine.43.945

M3 - Article

C2 - 15575245

AN - SCOPUS:8844256580

SN - 0918-2918

VL - 43

SP - 945

EP - 950

JO - Internal Medicine

JF - Internal Medicine

IS - 10

ER -

Marked improvement with sildenafil in a patient with primary pulmonary hypertension unresponsive to epoprostenol

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this